Business, Company updates & acquisitions, Dry eye, Local, News, Products, Therapeutics, Therapies

Aussie firm introduces NovaTears +Omega-3 eye drop

ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3.

The company has introduced NovaTears +Omega-3, which is now available in addition to the existing Pharmaceutical Benefits Scheme-listed NovaTears. German firm Novaliq manufactures the therapies.

Since 2018, NovaTears sales have increased year-on-year for AFT. The preservative-free therapy is a lipid layer stabiliser targeted at evaporative dry eye sufferers.

According to the company, NovaTears +Omega-3 is a unique eye lubricant and tear film stabiliser in a multi-dose bottle, also designed for the relief of evaporative dry eye disease and meibomian gland dysfunction.

It combines high quality and highly concentrated Omega-3 fatty acids of algae origin and Perfluorohexyloctane.

NovaTears +Omega-3 is also said to spread quickly and easily on the eye with a long-lasting effect; and provides enhanced lubrication and protection for dry and irritated eyes.

For product enquiries contact AFT Pharmaceuticals on 1800 238 742 or or  or for product orders contact Good Optical on 1800 814 963 or

Send this to a friend